News | October 08, 2024
AstraZeneca, CSPC Pharmaceutical agree for a pre-clinical novel lipid-lowering therapy
CSPC will receive an upfront payment of $100 million from AstraZeneca
CSPC will receive an upfront payment of $100 million from AstraZeneca
GSK and Flagship to jointly fund up to $150 million upfront
Vonoprozan is a novel potassium-competitive acid blocker used for the treatment of acid related disorders
225Ac-PSMA-Trillium is an investigational next-generation PSMA-targeted alpha therapy with potential to treat patients with advanced metastatic prostate cancer
Company reaffirms commitment to reduce the global burden of HPV-related diseases, including certain cancers
Through our research, we aim to ultimately provide new options for our customers to treat life-threatening infections in livestock
This agreement includes upfront and milestone payments with a combined potential value of over $500m and sales royalties.
Elpiscience will receive up to US $37 million, including the upfront payment and license option fees
C-CAR031 is based on a novel GPC3-targeting CAR-T (AZD5851) designed by AstraZeneca using their transforming growth factor-beta receptor II
Aim is to treat Dyslipidemia by inhibiting PCSK9 with a novel entity
Subscribe To Our Newsletter & Stay Updated
